KR950704301A - 항미생물제 5-히드라지노-퀴놀론 유도체(antimicrobial 5-hydrazino-quinolone derivatives) - Google Patents

항미생물제 5-히드라지노-퀴놀론 유도체(antimicrobial 5-hydrazino-quinolone derivatives)

Info

Publication number
KR950704301A
KR950704301A KR1019950701690A KR19950701690A KR950704301A KR 950704301 A KR950704301 A KR 950704301A KR 1019950701690 A KR1019950701690 A KR 1019950701690A KR 19950701690 A KR19950701690 A KR 19950701690A KR 950704301 A KR950704301 A KR 950704301A
Authority
KR
South Korea
Prior art keywords
compound
ring
heterocycle ring
cyclopropyl
fluorine
Prior art date
Application number
KR1019950701690A
Other languages
English (en)
Inventor
토마스 프로서 쥬니어 데무쓰
로날드 유젠 화이트
Original Assignee
제이코버스 코넬리스 레이서
더 프록터 앤드 갬블 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제이코버스 코넬리스 레이서, 더 프록터 앤드 갬블 캄파니 filed Critical 제이코버스 코넬리스 레이서
Publication of KR950704301A publication Critical patent/KR950704301A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

본 발명은 일반식(I)의 항미생물제 5-(N-헤테로치환된 아미노)퀴놀론 화합물 및 그의 약학적으로-허용 가능한 염 및 생가수분해가능한 에스테르, 및 그의 용매화물에 관한 것이며, 상기 일반식에서, (1) R1, R2및 R3은 항미생물 활성을 갖는 것으로 통해 당해 분야에 공지된 것과 유사한 다양한 퀴놀론 및 관련 헤테로사이클 구로조물을 형성하고; (2)(a)R4및 R5는 독립적으로 수소, 저급 알킬, 사이클로알킬, 헤테로알킬 또는 -C(=O)-X-R8(여기서 X는 공규결합, N, O 또는 S이고 R8은 저급 알킬, 저급 알케닐, 아릴알킬, 카보사이클 고리 또는 헤테로사이클 고리이다)이거나; 또는 (b)R4및 R5는 함께 이들이 결합한 질소를 포함한 헤테로사이클 고리를 포함한다.

Description

항미생물제 5-히드라지노-퀴놀론 유도체(ANTIMICROBIAL 5-HYDRAZINO-QUINOLONE DERIVATIVES)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. 하기 일반식의 화합물 및 그의 약학적으로 허용가능한 염 및 생가수분해 가능한 에스테르, 및 그의 용매화물 :
    상기식에서, (A)(1)(a)R1은 알킬; 알케닐; 카보사이클 고리; 헤테로사이클 고리; 또는 -N(R6)(R7)(여기서, R6및 R7은 독립적으로 수소, 알킬, 알케닐, 카보사이클 고리, 헤테로사이클 고리이거나, 또는 R6및 R7은 함께 이들이 결합되어 있는 질소를 포함하는 헤테로사이클 고리를 포함한다)이고; (b)R2는 수소, 할로겐, 저급 알킬 또는 저급 알콕시이거나; 또는 (2)R1및 R2는 함께 N′, 및 R2에 결합되어 있는 탄소원자를 포함하는 6원 헤테로사이클 고리를 포함할 수도 있고; (B)R3는 헤테로사이클 고리 또는 카보사이클 고리이고; (C)(1)R4및 R5는 독립적으로 수소; 저급 알킬; 사이클로알킬; 헤테로알킬; 또는 -C(=O)-X-R5(여기서, X는 공유결합, N,O 또는 S이고, R8은 저급 알킬, 저급 알케닐, 아릴알킬, 카보사이클 고리 또는 헤테로사이클 고리이다)이거나, 또는 (2)R4및 R5는 함께 이들이 결합되어 있는 질소를 포함하는 헤테로 사이클 고리를 포함한다.
  2. 제1항에 있어서, R1이 에틸, 2-플루오로에틸, 2-하이드록시에틸, t-부틸, 4-플루오로페닐, 2,4-디플루오로페닐, 메틸아미노, 사이클로프로필, 또는 2-플루오로사이클로프로필인 화합물.
  3. 제1항에 있어서, R2가 염소 또는 불소인 화합물.
  4. 제1항에 있어서, R4가 수소이고, R5가 수소 또는 저급 알킬인 화합물.
  5. 제4항에 있어서, R4및 R5가 둘다 수소인 화합물.
  6. 제5항에 있어서, R3가 헤테로사이클 고리인 화합물.
  7. 제6항에 있어서, 상기 헤테로사이클고리가 3-아미노피롤리딘인 화합물.
  8. 제7항에 있어서, R1이 사이크로프로필이고, R2가 불소인 화합물.
  9. 제7항에 있어서, R1이 2,4-디플루오로페닐이고, R2가 불소인 화합물.
  10. 제6항에 있어서, 상기 헤테로사이클 고리가 피페라진인 화합물.
  11. 제10항에 있어서, R1이 사이클로프로필이고, R2가 불소인 화합물.
  12. 제4항에 있어서, R5가 저급 알킬인 화합물.
  13. 제12항에 있어서, R3가 헤테로사리클 고리인 화합물.
  14. 제13항에 있어서, 상기 헤테로사이클 고리가 3-아미노피롤리딘인 화합물.
  15. 제14항에 있어서, R1이 사이클로프로필이고, R2가 불소인 화합물.
  16. 제13항에 있어서, 상기 헤테로사이클 고리가 피페라진인 화합물.
  17. 제16항에 있어서, R1이 사이클로프로필이고, R2가 불소인 화합물.
  18. (3S)-7-(3-아미노-1-피로리디닐)-1-(2,4-디플루오로페닐)-6,8-디플루오로-5-히드라지노-1,4-디하이드로-4-옥소-3-퀴놀린카복실산;
    (3S)-7-(3-아미노-1-피로리디닐)-1-사이클로프로필-6,8-디플루오로-5-히드라지노-1,4-디하이드로-4-옥소-3-퀴놀린카복실산; 및
    1-사이클로프로필-6,8-디플루오로-5-히드라지노-1,4-디하이드로-4-옥소-7-피페라지닐-3-퀴놀린카복실산으로 이루어진 그룹중에서 선택된 화합물 및 그의 약학적으로 허용가능한 염, 생가수분해가능한 에스테르 및 용매화물.
  19. (1)안전하고 효과적인 양의 제1항의 화합물; 및 (2)약학적으로 허용가능한 담체를 포함하는 인간 또는 다른 동물 환자의 감염증을 치료 또는 저해하기 위한 조성물.
  20. 인간 또는 다른 동물 환자에게 안전하고 효과적인 제1항의 화합물을 투여함으로써상기 환자의 감염증을 저해 또는 치료하는 방법.
    ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019950701690A 1992-10-30 1993-10-22 항미생물제 5-히드라지노-퀴놀론 유도체(antimicrobial 5-hydrazino-quinolone derivatives) KR950704301A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96896092A 1992-10-30 1992-10-30
US07/968,960 1992-10-30
PCT/US1993/010091 WO1994010163A1 (en) 1992-10-30 1993-10-22 Antimicrobial 5-hydrazino-quinolone derivatives

Publications (1)

Publication Number Publication Date
KR950704301A true KR950704301A (ko) 1995-11-17

Family

ID=25514997

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950701690A KR950704301A (ko) 1992-10-30 1993-10-22 항미생물제 5-히드라지노-퀴놀론 유도체(antimicrobial 5-hydrazino-quinolone derivatives)

Country Status (21)

Country Link
EP (1) EP0666853A1 (ko)
JP (1) JPH08502750A (ko)
KR (1) KR950704301A (ko)
CN (1) CN1064357C (ko)
AU (1) AU687018B2 (ko)
BR (1) BR9307347A (ko)
CA (1) CA2148003A1 (ko)
CZ (1) CZ282581B6 (ko)
EG (1) EG20543A (ko)
FI (1) FI952049A0 (ko)
HU (1) HUT72072A (ko)
IL (1) IL107323A (ko)
MX (1) MX9306814A (ko)
NO (1) NO951640L (ko)
NZ (1) NZ257470A (ko)
PL (1) PL178094B1 (ko)
RU (1) RU2126000C1 (ko)
SG (1) SG59979A1 (ko)
SK (1) SK54795A3 (ko)
WO (1) WO1994010163A1 (ko)
ZA (1) ZA938089B (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646163A (en) * 1992-10-30 1997-07-08 The Procter & Gamble Company Quinolone 5-(N-heterosubstituted amino) antimicrobials
JPH10503521A (ja) * 1994-08-02 1998-03-31 ザ、プロクター、エンド、ギャンブル、カンパニー キノロニルラクタム抗微生物剤の製造方法及び新規中間化合物
EP0775114B1 (en) * 1994-08-02 2000-03-22 The Procter & Gamble Company Process for making antimicrobial compounds
CN100395244C (zh) * 1996-02-09 2008-06-18 富山化学工业株式会社 喹诺酮羧酸衍生物或它们的盐类
PT1901749T (pt) * 2005-05-18 2016-11-04 Raptor Pharmaceuticals Inc Fluoroquinolonas aerossolizadas e suas utilizações
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
CA2528849C (en) 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
EA010601B1 (ru) * 2005-06-09 2008-10-30 Янссен Фармацевтика Н.В. Производные хинолина в качестве антибактериальных агентов
CN101020647B (zh) * 2007-02-14 2011-03-30 杭州师范学院 一种β-环丙胺基丙烯酸(酯)的合成方法
WO2008115890A2 (en) * 2007-03-19 2008-09-25 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
WO2009046383A1 (en) * 2007-10-05 2009-04-09 Cylene Pharmaceuticals, Inc. Quinolone analogs and methods related thereto
AU2009254738B2 (en) * 2008-06-03 2014-05-08 Idorsia Pharmaceuticals Ltd [4-(1-amino-ethyl) -cyclohexyl] -methyl-amine and [6-(1-amino-ethyl) -tetrahydro- pyran-3-yl] -methyl-amine derivatives as antibacterials
PL2344129T3 (pl) 2008-10-07 2018-07-31 Horizon Orphan Llc Formulacje fluorochinolonu w aerozolu dla poprawy właściwości farmakokinetycznych
JP2012505222A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 肺炎症を低減するためのレボフロキサシンの吸入
AR076222A1 (es) * 2009-04-09 2011-05-26 Actelion Pharmaceuticals Ltd Derivados 2-hidroxietil-1h-quinolin-ona y sus analogos azaisotericos con actividad antibacteriana y composiciones farmaceuticas que los contienen
ES2739979T3 (es) 2009-09-04 2020-02-05 Horizon Orphan Llc Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668680A (en) * 1985-12-12 1987-05-26 Warner-Lambert Company 5-amino-6,8-difluoroquinolones as antibacterial agents
JPH0228178A (ja) * 1988-04-23 1990-01-30 Toyama Chem Co Ltd 新規なピリドンカルボン酸誘導体およびその塩並びにそれらの製造法
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
WO1991002526A1 (en) * 1989-08-16 1991-03-07 Pfizer Inc. Azabicyclo quinolone carboxylic acids
JPH05506033A (ja) * 1990-04-18 1993-09-02 ノーウィッチ、イートン、ファーマスーティカルズ、インコーポレーテッド 抗微生物性キノロニルラクタム類
EP0559774B1 (en) * 1990-11-30 1999-07-07 Warner-Lambert Company Individual stereoisomers of 7- 3-(1-aminoalkyl)-1-pyrrolidinyl]-quinolones and naphthyridones as antibacterial agents

Also Published As

Publication number Publication date
FI952049A (fi) 1995-04-28
MX9306814A (es) 1994-07-29
JPH08502750A (ja) 1996-03-26
PL308671A1 (en) 1995-08-21
CZ282581B6 (cs) 1997-08-13
CA2148003A1 (en) 1994-05-11
SG59979A1 (en) 1999-02-22
NZ257470A (en) 1997-08-22
CZ109795A3 (en) 1995-12-13
WO1994010163A1 (en) 1994-05-11
SK54795A3 (en) 1995-12-06
EG20543A (en) 1999-07-31
AU5409794A (en) 1994-05-24
NO951640D0 (no) 1995-04-28
RU95110762A (ru) 1997-01-10
RU2126000C1 (ru) 1999-02-10
HU9501237D0 (en) 1995-06-28
NO951640L (no) 1995-06-30
IL107323A (en) 2000-06-01
FI952049A0 (fi) 1995-04-28
HUT72072A (en) 1996-03-28
AU687018B2 (en) 1998-02-19
ZA938089B (en) 1994-06-07
EP0666853A1 (en) 1995-08-16
CN1064357C (zh) 2001-04-11
PL178094B1 (pl) 2000-02-29
BR9307347A (pt) 1999-05-25
CN1092773A (zh) 1994-09-28
IL107323A0 (en) 1994-01-25

Similar Documents

Publication Publication Date Title
KR950704301A (ko) 항미생물제 5-히드라지노-퀴놀론 유도체(antimicrobial 5-hydrazino-quinolone derivatives)
RU2209813C2 (ru) Производные пиридазина, лекарственные средства на их основе и способ лечения артрита
KR930700450A (ko) 항미생물성 퀴놀론 티오우레아
YU49443B (sh) Derivati benzimidazola, postupci za njihovo pripremanje i primena tih derivata u medicinskoj terapiji, naročito za lečenje ili sprečavanje virusnih infekcija
CY1106977T1 (el) Χρησιμοποιηση παραγωγων χινολονης και χινολιζινονης σαν χημειοθεραπευτικα
RU2000115577A (ru) Новые производные пиридазина и лекарственные средства, содержащие их в качестве эффективных ингредиентов
HUP0203323A2 (hu) Tirozin kináz inhibitorok és ilyen vegyületeket tartalmazó gyógyászati készítmények
HUP0400710A2 (hu) Tioéter helyettesítővel helyettesített imidazokinolinszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
ATE232862T1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
ATE109481T1 (de) Diazinderivate als angiotensin ii rezeptor antagonisten.
ES2142861T3 (es) Derivados de 4-(1h-2-metilimidazo(4,5-c)piridinilmetil)fenilsulfonamida como antagonistas del paf.
EA200400223A1 (ru) Новые производные 2h-пиридазин-3-она, фармацевтические композиции, содержащие эти производные, и способ получения активного ингредиента
DE602005007769D1 (de) Neue derivate von porphyrin, insbesondere chlorine und bacteriochlorine und ihre verwendungen in der photodynamischen therapie
CA2137523A1 (en) One-pot process for the preparation of 3-quinolonecarboxylic acid derivatives
ATE186301T1 (de) An den positionen 2 und 9 substituierte 4h-pyrido-(1,2-a)pyrimidin-4-one
FI951858A0 (fi) Kinoloni- ja akridonijohdannaisia virtsanpidätyskyvyttömyyden hoidossa
NO912669D0 (no) Nye derivater av benzimidazol, deres fremstilling og anvendelse som legemidler.
KR900015733A (ko) 항-사람 면역결핍증 바이러스 조성물
DE69333285D1 (de) 2-heterozyklisch-5-hydroxy-1,3-pyrimidinen verwendbar als entzündungswidrigesmittel
SE9102909L (sv) Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms)
KR910011259A (ko) 뉴모시스토시스 치료 또는 예방에 사용하기 위한 플루오로퀴놀론 유도체로 구성된 약제
ATE237614T1 (de) Benzo(c)chinolizin derivate,deren herstellung und verwendung als 5-alfa-reduktase inhibitoren
CZ111095A3 (en) Derivatives of 3,4-dihydro-2(1h)-quinolone and pharmaceutical composition based thereon
NO971743L (no) Farmasöytisk sammensetning for profylakse og behandling av type I allergiske sykdommer
ES2121218T3 (es) Fenoxifenilciclopentenilhidroxiureas.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
NORF Unpaid initial registration fee